The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...